Back to the main directory
Company Analysis / Equity
- 2a Trials Seeding First Cohort; Potential for STING Agonist Highlighted. by Zacks
- NGX: Secured additional financing, to initiate pivotal Phase III trial of SGX-301 in 2H15 in collaboration with NORD and CLF--- Buy by Zacks
- SBOT: JV Consummated, Neovacs Lupus Candidate Closer To Commercialization by Zacks
- SBOT: Preparing To Scale in Anticipation of Growing Demand by Zacks
- SBOT: Uplists to NASDAQ, KLH Showing Promise in Alzheimer s Candidate by Zacks
- SBPH: Hep B - Large Market and Dominant Pricing Potential by Zacks
- SNGX: Cash burn very conservative, on track to advance multiple clinical programs --- Outperform by Zacks
- SNGX: Conservative cash burn, plan to initiate Phase III trial of SGX301---Outperform by Zacks
- SNGX: Market will eventually recognize the benefits of recent financing, Conservative cash burn, plan to initiate Phase III trial of SGX301---Outperform by Zacks
- SNGX: On track to advance multiple clinical programs, Balance sheet remains strong--- Outperform by Zacks
- SNGX: On track to initiate Phase III trial of SGX301---Outperform by Zacks
- SNGX: Phase III of SGX-301 initiated in collaboration with NORD and CLF, Positive data reported from Phase II of SGX942 for oral mucositis by Zacks
- SNGX: Positive data reported from Phase II of SGX942 for oral mucositis, Phase III of SGX-301 initiated in collaboration with NORD and CLF---Buy by Zacks
- SNGX: Positive data reported from Phase II of SGX942 for oral mucositis, Phase III of SGX-301 initiated in collaboration with NORD and CLF---Buy by Zacks
- SNGX: To initiate pivotal Phase III trial of SGX-301 in 2H15 in collaboration with NORD and CLF---Buy by Zacks
- SNGX: Balance sheet boosted by non-dilutive financing, on track to advance multiple clinical programs ---Outperform by Zacks
- Spring Bank Enters 3rd Collaboration. by Zacks
- 2Q:16 Results; Targets 4Q:16 LEVO-CTS Readout and LeoPARDS Data Receipt. by Zacks
- LEVO-CTS Enrolment Near Complete; Anticipate January Topline Readout. by Zacks
- Reports abbreviated CY15 and provides additional clarity regarding Phase 3 LEVO-CTS and LeoPARDS trials. by Zacks
- SPHS: Preparing for Phase 2b Trial of PRX302 in Prostate Cancer by Zacks
- TENX: FDA Approves Phase 3 LEVO-CTS Protocol Amendment by Zacks
- TENX: Patient Enrollment Accelerates in Phase 3 LEVO-CTS; Enrollment Complete for Phase 2 LeoPARDS Trial by Zacks
- TNXP: AFFIRM Study Does Not Meet Primary Endpoint; Company to Focus on Development of TNX-102 SL in PTSD by Zacks
- TNXP: TNX-102 SL Given Breakthrough Therapy Designation for PTSD… by Zacks
- Exited 2013 with cash on budget, on track to advance multiple clinical programs --- Outperform by Zacks
- SBOT: 2016 A Solid Year From Both Financial and Operational Perspective by Zacks
- SBOT: JV With Neovacs Offers Full Product Life Cycle Opportunity by Zacks
- SBOT: Q4 Inline. Heading Into 2016 Supporting More, Larger Clinical Trials by Zacks
- SBOTD: Initiating at Buy. Leveraging Demand for KLH in Immunotherapies by Zacks
- SNGX: Adjusting PT to $25 reflecting reverse stock split; Phase III of SGX-301 initiated in collaboration with NORD and CLF by Zacks
- SNGX: Conservative cash burn coupled with non-dilutive financing, on track to advance multiple clinical programs ---Outperform by Zacks
- SNGX: Long-term positive data reported from Phase II SGX942 reported; Phase III of SGX- 301 initiated in collaboration with NORD and CLF. by Zacks
- SNGX: On track to advance SGX942 and SGX-301 in 4Q15 in collaboration with NORD and CLF---Buy by Zacks
- SNGX: On track to advance multiple clinical programs, cash burn conservative ---Buy by Zacks
- SNGX: Phase II enrollment completed for SGX942, to initiate pivotal Phase III trial of SGX-301 in 2H15 in collaboration with NORD and CLF---Buy by Zacks
- SNGX: Positive data reported from Phase II of SGX942 for oral mucositis, Phase III of SGX-301 initiated in collaboration with NORD and CLF---Buy by Zacks
- SNGX: Positive data reported from Phase II of SGX942 for oral mucositis, Phase III of SGX-301 initiated in collaboration with NORD and CLF---Buy by Zacks
- SNGX: SGX943 and SGX101 may be a solution for Melioidosis, market will eventually recognize the benefits of recent financing, Conservative cash burn, plan to initiate Phase III trial of SGX301---Outperform by Zacks
- SNGX: entered late stage through the acquisition of Phase III ready candidate SGX301, conservative cash burn --- Outperform by Zacks
- Balance sheet remains strong, on track to move clinical programs by Zacks
- Though marginal, first positive lfl growth since 2014 by AlphaValue
- Announces study extension, but maintains original timeline for completion, readout and filing of IND for Phase 3 LEVO-CTS trial. by Zacks
- LeoPARDS Trial Fails to Meet Endpoints; Septic Shock Indication Dropped. Year End 2016 Readout for LEVOCTS Trial. by Zacks
- SPHS: Initiating on Sophiris Bio, Inc.; Developing Novel Treatments for Urologic Conditions… by Zacks
- TENX: Enrollment Picks Up for Phase 3 LEVO-CTS in LCOS as Phase 2b LeoPARDS in Septic Shock Nears Completion… by Zacks
- TENX: Initiating Coverage of Tenax Therapeutics, Inc.; Targeting Critical Care with Levosimendan… by Zacks
- TNXP: A Closer Look at the Use of MDMA for the Treatment of PTSD… by Zacks
- TNXP: Phase 3 Study of TNX-102 SL in PTSD to Initiate in 1Q17… by Zacks
- three platform technologies target multiple indications with focus on cancer supportive care, GI disorders as well as biodefense by Zacks